LIM domain only 1Genealiases: RBTN1 · RHOM1 · TTG1
Q-omics provides the consensus-scored LMO1 profile across patient tissues and cancer cell-line models. LMO1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LMO1 is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, LMO1 RNA expression shows 14,154 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KICH, and TGCT as cancer lineages where LMO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMO1 survival associations across molecular data types. LMO1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMO1 RNA expression–survival associations across cancer types. High LMO1 expression shows unfavorable associations in KIRP, BRCA, UCEC, KIRC, LIHC and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LMO1 RNA expression.
This table summarizes LMO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LMO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMO1 shows lower tumor expression in KICH, KIRC, BLCA and COAD and higher tumor expression in UCEC and LUSC. The KICH box plot shows higher LMO1 RNA expression in normal versus tumor tissue (log2 FC = −2.127, t-test p < 0.001).
This table shows molecular features associated with LMO1 in patient tissues and cancer cell lines. In patient samples, LMO1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LMO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
